151 related articles for article (PubMed ID: 23930097)
41. Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
[TBL] [Abstract][Full Text] [Related]
42. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
Buti M; Calleja JL; Lens S; Diago M; Ortega E; Crespo J; Planas R; Romero-Gómez M; Rodríguez FG; Pascasio JM; Fevery B; Kurland D; Corbett C; Kalmeijer R; Jessner W
Aliment Pharmacol Ther; 2017 Feb; 45(3):468-475. PubMed ID: 27896822
[TBL] [Abstract][Full Text] [Related]
43. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
45. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
46. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.
Mangia A; Foster GR; Berg CP; Curescu M; Ledinghen V; Habersetzer F; Manolakopoulos S; Negri E; Papatheodoridis G; Ahlers S; Castillo M; Bakalos G; Mauss S;
Ann Gastroenterol; 2017; 30(3):327-343. PubMed ID: 28469364
[TBL] [Abstract][Full Text] [Related]
48. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM
Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
[TBL] [Abstract][Full Text] [Related]
49. An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
Asselah T; Moreno C; Sarrazin C; Gschwantler M; Foster GR; Craxí A; Buggisch P; Ryan R; Lenz O; Scott J; Van Dooren G; Lonjon-Domanec I; Schlag M; Buti M
PLoS One; 2016; 11(7):e0158526. PubMed ID: 27428331
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
[TBL] [Abstract][Full Text] [Related]
51. Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F; McCone J; Bacon BR; Bruno S; Manns MP; Sulkowski MS; Jacobson IM; Reddy KR; Goodman ZD; Boparai N; DiNubile MJ; Sniukiene V; Brass CA; Albrecht JK; Bronowicki JP;
N Engl J Med; 2011 Mar; 364(13):1195-206. PubMed ID: 21449783
[TBL] [Abstract][Full Text] [Related]
52. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Koff RS
Aliment Pharmacol Ther; 2014 Mar; 39(5):478-87. PubMed ID: 24387618
[TBL] [Abstract][Full Text] [Related]
53. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.
Ahmed OA; Elsebaey MA; Fouad MHA; Elashry H; Elshafie AI; Elhadidy AA; Esheba NE; Elnaggar MH; Soliman S; Abd-Elsalam S
Infect Drug Resist; 2018; 11():441-445. PubMed ID: 29628768
[TBL] [Abstract][Full Text] [Related]
54. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
[TBL] [Abstract][Full Text] [Related]
55. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S
J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698
[TBL] [Abstract][Full Text] [Related]
56. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
El Raziky M; Gamil M; Ashour MK; Sameea EA; Doss W; Hamada Y; Van Dooren G; DeMasi R; Keim S; Lonjon-Domanec I; Hammad R; Hashim MS; Hassany M; Waked I
J Viral Hepat; 2017 Feb; 24(2):102-110. PubMed ID: 27790789
[TBL] [Abstract][Full Text] [Related]
57. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
58. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
[TBL] [Abstract][Full Text] [Related]
59. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
[TBL] [Abstract][Full Text] [Related]
60. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
